الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Endometrial cancer is the most common cancer of the female genital tract. No effective biomarkers currently exist to allow for an efficient risk classification of endometrial carcinoma or to direct treatment (adjuvant radiation and/or chemotherapy), or to triage pelvic and para-aortic lymphadenectomy. L1CAM a transmembrane protein of the immunoglobulin family that has been implicated in promoting tumor cell proliferation, migration, invasion, and metastasis became an attractive candidate as a potential biomarker in endometrial carcinoma and potential therapeutic target in high risk groups. Objectives: Evaluation of L1CAM expression in endometrial carcinoma and correlation of this expression with various pathological parameters. Material and methods: Immunohistochemical staining for L1CAM was performed on paraffin-embedded sections of 80 cases of endometrial carcinomas that underwent total hysterectomy with bilateral salpingo-oophorectomy. Expression of L1CAM in >10% of tumor cells was described as positive |